The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system.

by Sean M Geary, Caitlin D Lemke, David M Lubaroff, Aliasger K Salem
Published 2013-01-01

In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy

by Yinwen Cheng, Caitlin D Lemke-Miltner, Wattawan Wongpattaraworakul, Carlos H F Chan, Andrean L Simons
Published 2020-07-01

Monocytes Exposed to Immune Complexes Reduce pDC Type 1 Interferon Response to Vidutolimod

by Shakoora A. Sabree, Caitlin D. Lemke-Miltner, Sue E. Blackwell, Chaobo Yin, Aaron Bossler, Kareem Ebeid, Aliasger K. Salem, George J. Weiner
Published 2021-09-01

The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent

by Yinwen Cheng, Nicholas Borcherding, Ayomide Ogunsakin, Caitlin D. Lemke-Miltner, Katherine N. Gibson-Corley, Anand Rajan, Allen B. Choi, Wattawan Wongpattaraworakul, Carlos H. F. Chan, Aliasger K. Salem, George J. Weiner, Andrean L. Simons
Published 2021-01-01